DYRK1A and acute myeloid leukemia: In addition, it has been reported that DYRK1A plays a tumor‐suppressive role in AML by downregulating MYC (Liu et al, 2014); however, T‐025 treatment for 24 h had no effect on the endogenous or exogenous MYC expression in either SK‐MEL‐28 or U2OS cells.